BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
June 12, 2024 04:00 ET
|
AKAMPION
Favorable safety profile of resorbable breast scaffolds in one-year follow-upNo major scaffold-related complications or scaffold removals BellaSeno will initiate multicenter pivotal clinical trial...
Thermosome Appoints Dr. Sabine Hauck as Chief Technical Officer
June 11, 2024 04:00 ET
|
AKAMPION
- Experienced biopharma professional focused on drug product development Munich, Germany - June 11, 2024 - Thermosome, a drug development company focused on targeted tumor therapies, today...
BellaSeno Receives Financial Support Through Queensland’s Industry Partnership Program
June 05, 2024 04:00 ET
|
AKAMPION
Funding to support establishment of the world´s first fully automated production facility for resorbable medical scaffolds based in AustraliaAI-driven, no-touch manufacturing to ensure highest...
selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis
May 28, 2024 04:00 ET
|
AKAMPION
- New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity ...
Captain T Cell Secures Seed Financing Round Totaling € 8.5 Million
May 22, 2024 04:00 ET
|
AKAMPION
i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH and HIL-INVENT Ges.m.b.H. participated in the seed roundFunds will be used to accelerate a new generation of T cell therapies against solid tumors...
Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update
May 07, 2024 04:09 ET
|
AKAMPION
Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief...
selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
April 29, 2024 04:00 ET
|
AKAMPION
si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed75% of patients receiving si-544 experienced objective clinical improvement, of which 44%...
Mit biomedizinischer Forschung schneller zum Patienten: ForTra gGmbH gibt positive Förder-Bilanz bekannt
April 23, 2024 04:00 ET
|
AKAMPION
Lücke zwischen Grundlagenforschung und klinischer Anwendung schließenMehr als 50 Prozent aller geförderten Projekte erhalten Anschlussfinanzierung Bad Homburg v.d. Höhe, 23.04.2024 – Die...
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track Record
April 23, 2024 04:00 ET
|
AKAMPION
Closing the gap between basic research and clinical applicationMore than 50 percent of all funded projects received follow-up funding Bad Homburg v.d. Höhe, Germany, April 23, 2024 - ForTra gGmbH...
BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs
April 03, 2024 04:00 ET
|
AKAMPION
Further expansion of management expertise to accelerate BellaSeno´s market entry Leipzig, Germany, April 3, 2024 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable...